SRS MapCHECK半导体矩阵用于射波刀脊柱计划剂量验证的应用研究

目的:评估SRS MapCHECK半导体矩阵探测器用于射波刀脊柱计划剂量验证工作的适用性。方法:将SRS MapCHECK探测器安装于专用模体StereoPHAN开展研究工作，测试了射波刀固定和Iris可变准直器的单野计划，以及脊柱临床计划的质量保证（QA）计划，采用SNC Patient软件对比分析实测与计划剂量分布之间的差异，分别计算在2 mm/5%、2 mm/3%和2 mm/2%标准下的γ通过率。结果:在绝对剂量分析模式2 mm/5%，2 mm/3%和2 mm/2%标准下，固定和Iris可变准直器单野计划的γ通过率均为100.0%，脊柱QA计划的平均γ通过率分别为（99.3±1.2）%、（96.5±2.7）%和（93.5±5.3）%。结论:SRS MapCHECK半导体矩阵探测器在2 mm/5%和2 mm/3%的γ分析标准下适合用于开展射波刀脊柱临床计划的剂量验证工作。

Application of SRS MapCHECK semiconductor detector array in dose verification for spine CyberKnife plan

Abstract: Objective To evaluate the applicability of SRS MapCHECK semiconductor detector in dose verification for spine CyberKnife plan. Methods SRS MapCHECK detector was installed in the specific StereoPHAN phantom to conduct research. The single-field plans delivered by CyberKnife fixed and Iris variable collimators, as well as the quality assurance (QA) plans for spine clinical plans were tested. SNC Patient software was used to compare and analyze the differences between the measured and planned dose profiles, and the gamma passing rates for the criteria of 2 mm/5%, 2 mm/3% and 2 mm/2% were calculated. Results In absolute dose analysis mode and under the criteria of 2 mm/5%, 2 mm/3% and 2 mm/2%, all the gamma passing rates of the single-field plans delivered by fixed or Iris variable collimators reached 100.0%, and the average gamma passing rates of the spine QA plans were 99.3%±1.2%, 96.5%±2.7% and 93.5%±5.3%, respectively. Conclusion SRS MapCHECK semiconductor detector is suitable for the quick dose verification for spine CyberKnife plans under the gamma criteria of 2 mm/5% and 2 mm/3%.